(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of 9.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Tango Therapeutics's revenue in 2025 is $24,297,000.On average, 4 Wall Street analysts forecast TNGX's revenue for 2025 to be $5,621,980,281, with the lowest TNGX revenue forecast at $1,662,228,090, and the highest TNGX revenue forecast at $6,942,639,413. On average, 2 Wall Street analysts forecast TNGX's revenue for 2026 to be $3,047,974,467, with the lowest TNGX revenue forecast at $1,415,230,342, and the highest TNGX revenue forecast at $4,680,718,591.
In 2027, TNGX is forecast to generate $4,266,830,472 in revenue, with the lowest revenue forecast at $3,494,684,358 and the highest revenue forecast at $5,038,976,587.